WHO Policy Development Processes For A New Vaccine: Case Study of Malaria Vaccines
WHO Policy Development Processes For A New Vaccine: Case Study of Malaria Vaccines
WHO Policy Development Processes For A New Vaccine: Case Study of Malaria Vaccines
Open Access
CASE STUDY
Abstract
Background: Recommendations from the World Health Organization (WHO) are crucial to inform developing country
decisions to use, or not, a new intervention. This article analysed the WHO policy development process to predict its
course for a malaria vaccine.
Methods: The decision-making processes for one malaria intervention and four vaccines were classified through (1)
consultations with staff and expert advisors to WHO's Global Malaria Programme (GMP) and Immunization, Vaccines
and Biologicals Department (IVB); (2) analysis of the procedures and recommendations of the major policy-making
bodies of these groups; (3) interviews with staff of partnerships working toward new vaccine availability; and (4) review
and analyses of evidence informing key policy decisions.
Case description: WHO policy formulation related to use of intermittent preventive treatment in infancy (IPTi) and the
following vaccine interventions: Haemophilus influenzae type b conjugate vaccine (Hib), pneumococcal conjugate
vaccine (PCV), rotavirus vaccine (RV), and human papillomavirus vaccine (HPV), five interventions which had relatively
recently been through systematic WHO policy development processes as currently constituted, was analysed.
Required information was categorized in three areas defined by a recent WHO publication on development of
guidelines: safety and efficacy in relevant populations, implications for costs and population health, and localization of
data to specific epidemiological situations.
Discussion and evaluation: Data needs for a malaria vaccine include safety; the demonstration of efficacy in a range
of epidemiological settings in the context of other malaria prevention interventions; and information on potential
rebound in which disease increases subsequent to the intervention. In addition, a malaria vaccine would require
attention to additional factors, such as costs and cost-effectiveness, supply and demand, impact of use on other
interventions, and distribution issues.
Conclusions: Although policy issues may be more complex for future vaccines, the lead-time between the date of
product regulatory approval and a recommendation for its use in developing countries is decreasing. This study
presents approaches to define in advance core data needs to support evidence-based decisions, to further decrease
this lead-time, accelerating the availability of a malaria vaccine. Specific policy areas for which information should be
collected are defined, including studying its use within the context of other malaria interventions.
Background
It is a priority for both the PATH Malaria Vaccine Initiative (MVI) and the World Health Organization (WHO) to
determine the most appropriate role for a future malaria
vaccine in health systems of countries at risk for malaria
mortality and morbidity. The most advanced first-generation malaria vaccine candidate has shown promising
* Correspondence: [email protected]
3
Methods
Selection of interventions to study
The analysis was conducted by interviewing primary contacts (see acknowledgements) and reviewing documents
and websites related to the five interventions described
above. The authors adhered to the PRISMA guidelines
for improving the quality of reporting of systematic
reviews and meta-analyses to the extent possible [5].
Because the aim of this paper is to describe and systematize the interpretation of WHO policy, the authors consulted individuals from those departments in WHO who
contributed, or were relevant to, the decisions made by
the groups in question for the five interventions analyzed.
In addition selected non-WHO staff who led initiatives
specifically supporting WHO policy development were
identified and interviewed. In total 9 individuals were
identified across the 5 interventions. The authors
reviewed websites from IVB, the IVB Strategic Advisory
Group of Experts (SAGE), GMP, Roll Back Malaria Partnership (RBM) and the IPTi Consortium. The authors
reviewed every document indicated as reference docu-
Page 2 of 11
It is likely that two expert groups will consider future policy positions for a malaria vaccine: the Global Malaria
Programme (GMP) Strategic Technical Advisory Group
(STAG) and the Immunization, Vaccines and Biologicals
Department (IVB) SAGE. The GMP Director has only
recently established the STAG, charged with developing
malaria policy recommendations, based on expert inputs
[6]. Therefore, STAG's operating processes do not yet
have the history of the corresponding group for vaccines.
STAG is advisory ultimately to the Director-General of
WHO. Three technical expert groups (TEGs), on chemotherapy of malaria, vector control, and economics and
financing, report to STAG.
Within IVB, development of vaccine policy positions
rests with SAGE [7,8]. SAGE has existed in its current
configuration since November 2005 as the principal advisory group to the WHO Director-General for development of policy recommendations related to vaccines and
immunization. It is charged with advising WHO on policies and strategies on vaccines and technologies, research
and development, delivery of immunization, and their
linkages with other health interventions for all vaccine
preventable diseases, providing strategic advice rather
than technical inputs. The deliberations of SAGE take
into consideration the recommendations of two additional WHO expert groups, the Global Advisory Committee on Vaccine Safety (GACVS) and the Expert
Committee on Biological Standardization (ECBS) [9].
WHO policy recommendations on vaccine use are
expressed in WHO vaccine position papers published in
the Weekly Epidemiologic Record. Since April 2006, these
position papers have been fully discussed and endorsed
by SAGE prior to publication; every effort is made to
coordinate their publication as soon as possible after the
relevant SAGE meeting.
SAGE may consider a matter at least three times in
deciding whether or not to issue a policy recommendation. The first meeting is to inform SAGE members of
potential new interventions on the horizon. The second
meeting, which occurs when the potential intervention is
close to the finish, is extremely important, as it provides a
clear indication of the kinds of information SAGE would
need to make a global recommendation (i.e., a recommendation for use applicable to all target populations). If
all needed information is in place, the third meeting can
be the decision-making session, whether a utilization recommendation or a more limited position is solicited.
Since the SAGE process is dynamic and evolving, this
description may not hold in all cases.
Classification of data: WHO Guidelines
Table 1 summarizes the data available when policy positions were issued by the SAGE.
Haemophilus influenzae type b conjugate vaccine In
March 1998, WHO published the first position paper on
Hib [13]. At that time safety and efficacy data were available both in some developing countries, such as Chile, the
Gambia, and Uruguay [13], and in industrialized countries [14,15]. Efficacy was found to be at least 95 percent
against invasive Haemophilus influenzae type b disease
after three doses. There were no vaccine safety concerns.
However, there was little quantification of disease burden
outside of the industrialized world and most countries
did not have a surveillance system sufficiently tuned to
measure vaccine impact. The WHO position paper recommended the use of Hib in routine infant immunization
programmes in view of its demonstrated efficacy and
safety, but noted the lack of robust disease burden data in
Asia and in the Newly Independent States.
In 2003 and again in 2005, SAGE reviewed disease burden data in Asia [16,17], and in 2005 recommended
global implementation of Hib vaccination, unless there
were robust epidemiological evidence of low disease burden, lack of benefit, or overwhelming impediments to
implementation [17]. A new position paper on Hib was
then published in November 2006 [18]. This paper gave a
strong recommendation for Hib use, stating clearly that
Page 3 of 11
Page 4 of 11
Table 1: Analysis of data available for SAGE vaccine decisions according to WHO Guidelines document criteria
Intervention
Hib
PCV
RV
HPV
IPTi
Year of licensing
1988
2000
2004
2006
NA
<1998
1999
2004
2006
NA
1998
2003
2005
2007
2006
2006
2005
2009
2008
2009
2005
2005
2004
2007
2004
2006
2006
2005
2008
2009
2006
2006
--
2009
2009
Localization of data
Logistics issues addressed
NA
--
--
2007
2006
2003
2003
2005
2008
2009
2005
NA
2006
2008
2009
Nov 2006
Mar 2007
Jun 2009
Oct 2009
The situation and conclusions of the meeting were captured in an updated WHO position paper published in
2003 [32], with a strong recommendation that future vaccines should be concomitantly tested in industrialized
and developing countries.
In 2004 [33], SAGE was briefed on the development of
additional RV candidates, one of which, developed by
GlaxoSmithKline Biologicals (GSK), had been licensed in
Mexico. This, and another candidate, developed by
Merck & Co (Merck), had undergone large-scale clinical
trials in Latin America, as well as in the industrialized
world, with strong evidence of safety and efficacy [34,35].
Additional trials were being initiated in Asia and Africa,
which would also investigate the question of potential RV
interference with oral polio vaccine.
Considering data assembled by the PATH Rotavirus
Vaccine Programme, SAGE in November, 2005 [17]
requested, more information from Africa and Asia where
the disease burden was very high, as well as evidence of
potential financing mechanisms. SAGE also recognized
the importance of post-marketing surveillance to assess
safety in real-life situations, and supported previous
WHO recommendations for obtaining information on
Page 5 of 11
have been approved for financial support, and an additional 11 are projected to apply soon [41,42]. Uniquely,
the vaccine was introduced into Latin American countries in parallel with introduction into developed countries.
Human papillomavirus vaccine The first time this vaccine was presented to SAGE was at its November 2005
meeting [17]. SAGE noted the potential communications
challenges that might exist for a vaccine against a sexually
transmitted disease, and suggested the need to study the
impact of population screening in conjunction with the
vaccine, and the financial implications of such a course.
SAGE was updated in subsequent meetings on the
global burden of cervical cancer and the available data on
safety, efficacy, and immunogenicity of the two candidate
vaccines [43]. In addition, work on cost-effectiveness and
vaccine delivery options was described, along with ongoing research on alternative schedules, delivery costs, and
acceptability. The particular areas of SAGE focus were
that the use of the vaccine was likely to bring great benefits in settings with high cervical cancer burden, especially in countries where screening programmes were
limited or non-existent; that data on long-term duration
of protection would be important in planning vaccine
delivery strategies, especially the need for a booster dose;
that the issue of delivery strategies would be critical, as
immunizing adolescents entails an expansion into a new
target group; and it noted the current high price of the
vaccine licensed in industrialized countries [44].
At its June 2007 meeting, the IVB GACVS had determined that there were no outstanding safety issues with
use of the vaccine [45]. Work to clarify the issues and to
develop candidate recommendations was performed by
an HPV Expert Advisory Group (HEAG), which was later
reconstituted as the HPV Advisory Committee (HVAC)
[46].
Candidate recommendations were presented to SAGE
in November 2008 [39], and at that time SAGE recommended that HPV be included in all national immunization programs, provided that (1) prevention of cervical
cancer and other HPV-related diseases is a public health
priority; (2) an introduction program is nationally feasible; (3) sustainable financing is available; and (4) costeffectiveness of an HPV intervention is considered. A
WHO position paper was published in April 2009 [47].
The work on HPV is an important model for the evolution of policy positions for malaria vaccines, in light of
the use of an Expert Advisory Group which included
experts in immunization, reproductive health, and cancer
to put the requisite data into a background paper and to
draft potential positions on vaccine use. A malaria vaccine policy recommendation is also likely to require participants representing a wide group of disciplines. Also,
This analysis originally considered four malaria interventions, including artemisinin-based combination therapy,
insecticide-treated nets, intermittent preventive treatment in pregnancy, and IPTi. Due to changes in the
malaria policy-making structure, the processes used and
the completeness of data available for review were not
deemed appropriate to this discussion for the first three
interventions; thus only IPTi is considered.
IPTi uses the national immunization program to distribute the anti-malarial sulphadoxine-pyrimethamine
(SP) to children during routine immunization contacts.
An analysis of the decision-making process associated
with the development of an IPTi policy is instructive in
that it has incorporated the policy development processes
of both the GMP STAG and the IVB SAGE.
Promising research results using IPTi from Tanzania
[48-50], Ghana [51], and Mozambique [52] are available,
and thus the GMP, along with the IPTi Consortium, outlined a policy development plan for this intervention [53],
which included consideration by the relevant technical
expert groups to GMP (namely, the TEG on Chemotherapy of Malaria and the STAG) and by SAGE.
Because of the SAGE policy of "horizon scanning", the
use of IPTi had already been considered in April 2006
[54]. At that time SAGE was presented with the following
information [8]: malaria disease burden in sub-Saharan
Africa; pooled data from five safety and efficacy studies in
sub-Saharan Africa; pooled data from three studies on
impact of the intervention on serology vs routine infant
vaccines; data from two cost-effectiveness studies; information on drug resistance; and one year of implementation experience.
SAGE, after reviewing data from these five trials, and
noting declining efficacy, likely related to SP resistance,
asked for more safety and efficacy data in relevant populations, including longer term follow-up to rule out
rebound (i.e. increasing disease burden later in life) and
to indicate efficacy if the putative immunization schedule
were not rigorously followed. SAGE also requested more
information on the impact of IPTi on alternative malaria
control interventions already in force, as well as the usefulness of such a strategy in areas with only seasonal
malaria transmission.
The GMP's TEG on Chemotherapy of Malaria met in
Geneva in October 2006 [55]. The group reviewed 11
Page 6 of 11
Page 7 of 11
In the case of IPTi, the need for further safety and efficacy data had been the major factor in delaying a policy
recommendation for both the SAGE and the TEG. However, both groups have considered other factors, such as
impact on other interventions and disease characteristics,
and impact on EPI through pilot projects.
Data needs for malaria vaccine policy positions
trial design. Some of the issues noted above were presented as having already been considered by an "Initiative
for Vaccine Research-Global Malaria Programme Joint
Technical Expert Groups on Malaria Vaccines Entering
Pivotal Phase III Trials and Beyond."
Table 2 includes information based upon the previous
analyses, which is likely to be needed to inform policy
positions on malaria vaccines. This information could be
the target of further refinement by WHO, and in the
meantime provides indications of the data that those
working on malaria vaccines should strive to address during the development process.
Page 8 of 11
Conclusions
With the above as background, several conclusions can
be drawn:
1. Although efficacy and safety in the relevant target
population, including displacement of disease to
another susceptible age range, are crucial components of any policy development process, additional
concerns may also be important in the formulation of
policy positions. These include issues related to costs
and population health, such as supply and demand
issues, financing issues, cost-effectiveness, the impact
Safety
An acceptable safety profile
Freedom from "rebound" effect, that is, enhancing
disease incidence in target groups following use:
needs follow-up population monitoring
Positive evaluation from WHO GACVS
No significant adverse impact on other malaria
prevention and treatment strategies (i.e. increasing
adverse events from another product) or on
response to concomitantly administered vaccines
Safety evaluated in immunologically compromised
groups, e.g. HIV-infected
Efficacy
Acceptable level of reduction of disease-related
morbidity and/or mortality in target populations
Efficacy demonstrated in different malaria
endemicity settings
Delivery schedules, dosing and administration route
feasible and consistent with burden of disease in
target countries
Implications
for costs and
population
health
Localization
of data
Page 9 of 11
Acknowledgements
The authors are pleased to acknowledge useful inputs without which this
paper would not have been possible from Philippe Duclos, Vasee Moorthy,
Zarifah Reed (currently affiliated with Regional Emerging Diseases Intervention
(REDI) Centre, Singapore) and Kamini Mendis, WHO; from Jane Crawley, IPTi
Consortium and UK Medical Research Council Clinical Trials Unit; Rana Hajjeh,
the Hib Initiative, Johns Hopkins University Bloomberg School of Public Health;
Orin Levine, International Vaccine Access Center, Johns Hopkins Bloomberg
School of Public Health; Stephanie Schrag, Centers for Disease Control and Prevention; and John Wecker, PATH Rotavirus Vaccine Program. The authors are
not affiliated with WHO and this paper does not necessarily represent the
views of WHO.
This work was supported by funding from the Bill and Melinda Gates Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Details
of Maryland School of Medicine, 3 bis rue des Coronilles Rsidence
Parc de Clmentville Btiment C, 34070 Montpellier, France, 2PATH Malaria
Vaccine Initiative, 7500 Old Georgetown Road, #1200 Bethesda, MD 20814, USA
and 3PATH, 13 Chemin du Levant, 01210 Ferney-Voltaire, France
1University
This
Malaria
2010
is
article
an
Milstien
Journal
Open
is available
Access
2010,
et al; licensee
9:182
from:
articlehttp://www.malariajournal.com/content/9/1/182
distributed
BioMed Central
underLtd.
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J,
Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P,
Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC,
Demoiti MA, Dubovsky F, Menndez C, Tornieporth N, Ballou WR,
Thompson R, Cohen J: Efficacy of the RTS,S/AS02A malaria vaccine
against Plasmodium falciparum infection and disease in young African
children: randomized control trial. Lancet 2004, 364:1411-1420.
2. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B,
Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S,
Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J,
Thompson R, Ballou WR: Duration of protection with RTS,S/AS02A
malaria vaccine in prevention of Plasmodium falciparum disease in
Mozambican children: single-blind extended follow-up of a
randomized control trial. Lancet 2005, 366:2012-2018.
3. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S,
Lang T, Gould J, Dubois MC, Demoiti MA, Stallaert JF, Vansadia P,
Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S,
Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley
EM, Lemnge MM, Marsh K, von Seidlein L: Efficacy of RTS,S/AS01E
vaccine against malaria in children 5 to 17 months of age. N Engl J Med
2008, 359:2521-2532.
4. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S,
Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T,
Schellenberg DM, Carter T, Villafana T, Demoiti MA, Dubois MC, Leach A,
Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M: Safety and
immunogenicity of RTS,S/AS02 malaria vaccine in infants. N Engl J Med
2008, 359:2533-2544.
5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gtzsche PC, Ioannidis JP,
Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA Statement for
Reporting Systematic Reviews and Meta-Analyses of Studies That
Evaluate Health Care Interventions: Explanation and Elaboration. PLoS
Med 2009, 6:e1000100. Epub 2009 Jul 21
6. Global Malaria Programme [http://www.who.int/malaria]
7. Immunization Vaccines and Biologicals [http://www.who.int/
immunization/en]
8. Strategic Advisory Group of Experts [http://www.who.int/
immunization/sage/en/index.html]
9. Duclos P, Okwo-Bele J-M: Recommandations et politiques vaccinales
mondiales. Le rle de l'OMS. Med Sci (Paris) 2007, 23:409-416.
10. Global Programme on Evidence for Health Policy. In Guidelines for WHO
Guidelines Geneva: World Health Organization; 2003. EIP/GPE/EQC/2003.1
11. Oxman AD, Lewis JN, Fetheim A: Use of evidence in WHO
recommendations. Lancet 2007, 369:1883-1889.
Page 10 of 11
34. Heaton PM, Goveia MG, Miller JM, Offit P, Clark HF: Development of a
pentavalent rotavirus vaccine against prevalent serotypes of rotavirus
gastroenteritis. J Infect Dis 2005, 192(Suppl 1):S17-21.
35. De Vos B, Vesikari T, Linhares AC, Salinas B, Prez-Schael I, Ruiz-Palacios
GM, Guerrero Mde L, Phua KB, Delem A, Hardt K: A rotavirus vaccine for
prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis
J 2004, 23(10 Suppl):S179-82.
36. Enhanced Diarrheal Disease Control Resource Center [http://
www.eddcontrol.org]
37. World Health Organization: Rotavirus vaccines. Wkly Epidemiol Rec 2007,
82:285-296.
38. World Health Organization: Evaluating clinical trial data and guiding
future research for rotavirus vaccines. Wkly Epidemiol Rec 2008,
83:385-392.
39. World Health Organization: Meeting of the immunization Strategic
Advisory Group of Experts, November 2008 - conclusions and
recommendations. Wkly Epidemiol Rec 2009, 84:1-16.
40. World Health Organization: Meeting of the immunization Strategic
Advisory Group of Experts, April 2009 - Conclusions and
recommendations. Wkly Epidemiol Rec 2009, 84:213-236.
41. Ranjana Kumar: Presentation - Update and Future Directions for the
Global Alliance for Vaccines and Immunization. [http://
www.rotavirusvaccine.org/index.htm].
42. Nicaraguan Vaccination Program [http://www.merck.com/
responsibility/access/access-feature-nicaraguan.html]
43. Centers for Disease Control and Prevention (CDC): Quadrivalent Human
Papilloma Vaccine. Recommendations of the Advisory Committee on
Immunization Practices (ACIP). Morb Mortal Wkly Rep 2007,
56(RR02):1-24.
44. World Health Organization: Meeting of the Immunization Strategic
Advisory Group of Experts, November 2007 - Conclusions and
Recommendations. Wkly Epidemiol Rec 2008, 83:1-16.
45. World Health Organization: Global Advisory Committee on Vaccine
Safety. Wkly Epidemiol Rec 2007, 82:245-260.
46. World Health Organization: Meeting of the immunization Strategic
Advisory Group of Experts, November 2007 - Conclusions and
recommendations. Wkly Epidemiol Rec 2008, 83:1-16.
47. World Health Organization: Human papillomavirus vaccines. WHO
position paper. Wkly Epidemiol Rec 2009, 84:118-131.
48. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M,
Mshinda H, Alonso P: Intermittent treatment for malaria and anaemia
control at time of routine vaccinations in Tanzanian infants: a
randomised placebo-controlled trial. Lancet 2001, 357:1471-1477.
49. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M,
Mshinda H, Alonso P: Effect of intermittent treatment with
amodiaquine on anaemia and malarial fevers in infants in Tanzania: a
randomised placebo-controlled trial. Lancet 2003, 361:1853-1860.
50. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H,
Alonso P: Intermittent preventive antimalarial treatment for Tanzanian
infants: follow-up to age 2 years of a randomised, placebo-controlled
trial. Lancet 2005, 365:1481-1483.
51. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano
K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B: Cluster
randomised trial of intermittent preventive treatment for malaria in
infants in area of high, seasonal transmission in Ghana. BMJ 2005,
331:727-733.
52. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, Sigauque B,
Dobao C, Mabunda S, DgeDge M, Alonso P, Menendez C: Intermittent
preventive treatment for malaria control administered at the time of
routine vaccinations in Mozambican infants: a randomized, placebocontrolled trial. J Infect Dis 2006, 194:276-285.
53. IPTi Consortium [http://www.ipti-malaria.org]
54. World Health Organization: Meeting of the immunization Strategic
Advisory Group of Experts, Geneva, 10-11 April, 2006: Conclusions and
recommendations. Wkly Epidemiol Rec 2006, 81:209-220.
55. World Health Organization: Report of Technical Consultation on Intermittent
Preventive Treatment for Malaria in Infancy (IPTi) Global Malaria Programme,
World Health Organization, Geneva; 2006:25-27.
56. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I:
Is the Expanded Programme on Immunisation the most appropriate
57.
58.
59.
60.
61.
62.
doi: 10.1186/1475-2875-9-182
Cite this article as: Milstien et al., WHO policy development processes for a
new vaccine: case study of malaria vaccines Malaria Journal 2010, 9:182
Page 11 of 11